@article {CLOUSTON2635, author = {HAMISH WILLIAM CLOUSTON and PETER ADAM REES and REBECCA LAMB and SARAH ELIZABETH DUFF and CLIONA CLARE KIRWAN}, title = {Effect of Tissue Factor on Colorectal Cancer Stem Cells}, volume = {38}, number = {5}, pages = {2635--2642}, year = {2018}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Tissue factor (TF) expression increases cancer stem cell (CSC) activity in breast and lung cancer. There are ongoing studies focused on targeting CSCs via anti-TF treatment, for breast and lung cancer therapy. Herein, the aim was to determine whether targeting TF could have an anti-CSC therapeutic role in colorectal cancer (CRC). Materials and Methods: Evaluation of colonosphere-forming efficiency (CFE) and aldehyde dehydrogenase (ALDH) expression level was used to quantify CSC activity in two CRC cell lines, after TF knockdown (TFKD) or TF over-expression (TFOE). Results: TFKD resulted in increased levels of ALDH in SW620 (1.31{\textpm}0.04-fold, p\<0.001) and DLD-1 (1.63{\textpm}0.14-fold, p=0.04) cells. CFE was increased in SW620 (1.21{\textpm}0.23\% vs. 2.03{\textpm}0.29\%, p=0.01) and DLD-1 (0.41{\textpm}0.12\% vs. 0.68{\textpm}0.9\%, p=0.01) cells. Conversely, TFOE decreased ALDH expression (0.72{\textpm}0.04-fold, p=0.001) and CFE (0.33{\textpm}0.05\% vs. 0.66{\textpm}0.14\%, p=0.006) in DLD-1, but had no impact on SW620 cells. Conclusion: In the examined CRC cell lines, TF expression was inversely related to CSC activity suggesting that anti-TF therapies may not have a role in CRC treatment.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/38/5/2635}, eprint = {https://ar.iiarjournals.org/content/38/5/2635.full.pdf}, journal = {Anticancer Research} }